Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Ikonisys Secures EUR 2.72 Million Through Capital Increase and Debt Conversion with Avantgarde Srl and Alberto Previtali.

Dec 19, 2025•6 months ago

Contract Type

contract

ParigiBiotechnologyHealth Care

Description

Ikonisys has completed a capital increase of EUR 1.5 million and converted EUR 1.22 million of debt into capital, resulting in a total round of EUR 2.72 million. This investment was backed by Avantgarde Srl and investor Alberto Previtali, signaling strong support for the company's growth strategy.

Company Information

Company

Ikonisys

Location

Parigi, Ile De France, France

About

Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform, Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring. Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine, empowering clinicians to deliver targeted therapies and improve patient outcomes.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Ikonisys's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months